Myricx Bio Raises £90M for Cancer Drug Development
Myricx Bio, a London, UK-based biotech company, recently announced that it has successfully raised £90M ($114M) in Series A funding. The funding round was led by Novo Holdings and Abingworth, with additional new investors including British Patient Capital (BPC), Eli Lilly & Company, as well as current investors Sofinnova Partners and Brandon Capital. Founded by Prof Ed Tate, Dr Roberto Solari, and Dr Andrew Bell, and currently led by CEO Dr Robin Carr, Myricx Bio is at the forefront of developing a revolutionary new payload class for antibody-drug conjugates (ADCs).
The team at Myricx Bio is dedicated to the discovery and development of a completely unique class of payloads for ADCs focused on inhibiting N-myristoyltransferases (NMT) to effectively target cancer cells.
With the ADC field currently dominated by microtubule and topoisomerase inhibitors, Myricx's innovative approach aims to provide patients with a more diverse and effective treatment option. By targeting key protein targets essential for cancer cell survival, NMT inhibitors have shown promising results in achieving complete and durable tumor regressions in multiple solid cancer models.
The recent funding injection will enable Myricx Bio to advance its proprietary pipeline of N-Myristoyltransferase inhibitor (NMTi) ADCs through clinical proof of concept, focusing on clinically validated tumor-associated antigens to address critical unmet needs in oncology. As a spinout from Imperial College London and the Francis Crick Institute, Myricx Bio plans to establish laboratory operations in London and expand its Management and R&D teams to further drive innovation in the biotech sector.
They've invested in Myricx Bio
Get to know these Biotech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Novo Holdings | 4 investment(s) investment(s) | more info | |||
2 |  Abingworth | 1 investment(s) investment(s) | more info | |||
3 |  British Patient Capital (BPC) | 1 investment(s) investment(s) | more info | |||
4 |  Eli Lilly & Company | 1 investment(s) investment(s) | more info | |||
5 |  Sofinnova Partners | 7 investment(s) investment(s) | 29 contacts contacts |
Click here for a full list of 6,481+ startup investors in the UK